Corbus Pharma

Corbus Pharma Corbus Pharma is committed to leveraging its expertise in immunology to fulfill its purpose of developing innovative new medicines that improve lives.

08/05/2025

“The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all three of our clinical programs,” said Yuval Cohen, Ph.D., Corbus CEO. Read more for key corporate and program updates: https://bit.ly/453kpfr

08/05/2025

Corbus today provided a corporate update and reported financial results for the quarter ended June 30, 2025. For details: https://bit.ly/453kpfr

07/30/2025

Corbus announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 (SYS6002) has been accepted for presentation as a poster at the European Society for Medical Oncology (ESMO) Congress 2025, to be held October 17-21, 2025 in Berlin, Germany. For details: https://bit.ly/46AoZDc

07/01/2025

Corbus has initiated the MAD portion of the Phase 1 study of CRB-913 for the treatment of obesity. No treatment-related neuropsychiatric events have been seen to-date in the SAD portion and the MAD portion is on track for completion in Q3 2025. https://bit.ly/4kjUp3P $CRBP

07/01/2025

Corbus announced the initiation of the MAD portion of the Phase 1 study of CRB-913 for the treatment of obesity. No treatment-related neuropsychiatric events have been seen to-date in the SAD portion of Phase 1 study and the MAD portion is on track for completion in Q3 2025. Learn more: https://bit.ly/4kjUp3P

06/30/2025

Our CEO, Yuval Cohen, Ph.D., comments on the initiation of the multiple ascending dose portion of the Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Learn more about the study: https://bit.ly/4kjUp3P

06/30/2025

Corbus today announced the initiation of the multiple ascending dose (MAD) portion of its Phase 1 trial for CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. This follows safety data analysis of the single ascending dose (SAD) study launched in March. The MAD portion of this clinical study is scheduled for completion in the second half of this year. For more: https://bit.ly/4kjUp3P

06/26/2025

Corbus recently announced the first patient dosed with its Nectin-4 targeting ADC CRB-701 in combination with pembrolizumab. The combination cohort was initiated following successful review of the monotherapy cohort, with over 100 participants dosed to-date in the monotherapy cohort. For more: https://bit.ly/3HVzw1m

06/26/2025

Attending the Piper Sandler 3rd Annual Virtual Obesity Symposium? Corbus CEO, Yuval Cohen, Ph.D., will participate in a fireside chat today, June 26th at 10 a.m. ET. https://bit.ly/3GcVQTC

06/25/2025

Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus comments on the dosing of the first patient with Corbus' Nectin-4 targeting ADC CRB-701 in combination with Keytruda® (pembrolizumab). Learn more: https://bit.ly/3HVzw1m

06/25/2025

Corbus today announced the dosing of the first participant in the PD-1 combination arm of its Phase 1 study investigating CRB-701 in solid tumors (the Phase 1 Western study). Participants in this arm of the study are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts in combination with Keytruda® (pembrolizumab). For details: https://bit.ly/3HVzw1m

06/24/2025

Corbus CEO, Yuval Cohen, Ph.D., will participate in a fireside chat at the Piper Sandler 3rd Annual Virtual Obesity Symposium, to be held on June 26, 2025. The event will include presentations by key opinion leaders and fireside chats with companies developing obesity therapeutics. For details: https://bit.ly/3GcVQTC

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Corbus Pharma:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier pe*******on and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.